AstraZeneca PLC Files 6-K Report

TL;DR

AZN filed a 6-K, important notice for investors, check Form 20-F.

AI Summary

AstraZeneca PLC filed a Form 6-K on September 29, 2025, to report information as a foreign private issuer. The filing indicates that AstraZeneca is required to file annual reports under Form 20-F. The document is important and requires immediate attention, recommending recipients seek financial advice if in doubt.

Why It Matters

This filing serves as an official notification to the SEC and investors about AstraZeneca's reporting status and the importance of the document for understanding the company's ongoing disclosures.

Risk Assessment

Risk Level: low — This is a routine administrative filing by a large, established company and does not contain specific financial or operational news that would typically increase risk.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• SEC (company) — Recipient of the filing
• Form 6-K (document) — Type of filing
• Form 20-F (document) — Annual report form

FAQ

From the Filing

0001104659-25-094039.txt : 20250929 0001104659-25-094039.hdr.sgml : 20250929 20250929060805 ACCESSION NUMBER: 0001104659-25-094039 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20250929 FILED AS OF DATE: 20250929 DATE AS OF CHANGE: 20250929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251351991 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 tm2526326-11_6k.htm 6-K tm2526326-11_6k - none - 4.6392251s TABLE OF CONTENTS ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F: Form 20-F ☒ Form 40-F ☐ ​ ​ TABLE OF CONTENTS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own personal financial advice immediately from an appropriately authorised stockbroker, bank manager, solicitor, accountant or other independent financial adviser who, if you are taking advice in the United Kingdom (“UK”), is duly authorised by the Financial Services and Markets Act 2000 (“FSMA”), or, if you are not resident in the UK, from another appropriately authorised independent financial adviser in your own jurisdiction. If you sell or have sold or otherwise transferred all of your shares in AstraZeneca PLC (“ AstraZeneca ”), please send this document and any accompanying documents or forms (other than documents or forms personalised to you) as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom you sell or have sold or transferred your shares for delivery to the purchaser or transferee. If you have sold or otherwise transferred only part of your holding of AstraZeneca Shares (as defined below), please consult the bank, stockbroker or other agent through whom the sale or transfer was effected as to the action you should take. This document is not a prospectus or prospectus-equivalent document and it does not constitute or form part of any offer or invitation to purchase, acquire, subscribe for, sell, dispose of or issue, or any solicitation of any offer to purchase, acquire, subscribe for, sell or dispose of, any security, including any AstraZeneca Shares. ​ AstraZeneca PLC  (incorporated in England and Wales with registered number 02723534) Proposed implementation of Harmonised Listing Structure involving a direct listing of AstraZeneca Shares on the NYSE and Notice of General Meeting ​ You should read the whole of this document. Your attention is drawn to the letter from the Chair of AstraZeneca which is set out in Part I ( Letter from the Chair of AstraZeneca PLC ) and Part II ( Explanation of the proposals to implement the Harmonised Listing Structure ) and which contains the unanimous recommenda